[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Abbott\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":77},{"warningLetters":4,"total":76},[5,34,57],{"id":6,"raw":7,"subject":15,"body_html":16,"body_text":17,"firm_name":18,"letter_id":19,"created_at":20,"fei_number":21,"letter_url":22,"updated_at":23,"action_type":24,"case_status":25,"posted_date":26,"marcs_cms_no":27,"product_type":28,"closeout_date":29,"issuing_office":11,"recipient_name":30,"body_fetched_at":31,"delivery_method":32,"recipient_title":21,"reference_number":21,"action_taken_date":33,"medical_device_id":21,"response_letter_date":21},1784,[8,9,10,11,12,13,14,13],"\u003Ctime datetime=\"2023-10-25T18:45:00Z\">10\u002F25\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-10-24T04:00:00Z\">10\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-10242023\">Abbott Laboratories\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Dietary Supplement\u002FAdulterated\u003Cbr \u002F>\r\n","","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-12122024\">\u003Ctime datetime=\"2025-01-21T05:00:00Z\">01\u002F21\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Dietary Supplement\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics\u003Cbr>Dietary Supplements\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Robert B. Ford\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abbott Laboratories\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>100 Abbott Park Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Abbott Park\u003C\u002Fspan>, \u003Cspan>IL\u003C\u002Fspan> \u003Cspan>60064\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:robert.ford@abbott.com\"> robert.ford@abbott.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Date: October 24, 2023\u003C\u002Fp>\n\n\u003Cp>Warning Letter #669353\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ford:\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s websites at www.abbottnutrition.com, www.abbott.com, and www.pediatricproconnect.com in October 2023 and your company’s marketing materials for Similac® Probiotic Tri-Blend (hereinafter Similac Probiotic Supplement or your product), which contains instructions on where to buy your product. The marketing materials FDA reviewed include one handout that bears the heading “Probiotics and Preterm Infants: Clinical Evidence” and another that bears the heading “The Promise of Similac Another Innovation Only From Similac,” which your sales representatives provided together to hospital staff. You refer to your product as a probiotic and offer it for sale to health care professionals in the United States. Your product is labeled as containing, among other ingredients, \u003Cem>Bifidobacterium infantis\u003C\u002Fem> (Bb-02) and&nbsp;\u003Cem>Streptococcus thermophilus\u003C\u002Fem> (TH-4®), otherwise known as \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) and \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), and you sell it for use in preterm infants.\u003C\u002Fp>\n\n\u003Cp>Based on the statements on your website and your marketing materials, your product is an unapproved new drug and unlicensed biological product that you introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. Your Similac Probiotic Supplement is also adulterated under section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)] because it contains \u003Cem>B. infantis\u003C\u002Fem> (Bb-02), an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act [21 U.S.C. §§321(s) and 348]; and \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, when used in preterm infants. These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>As explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&amp;C Act and the PHS Act. You can find the FD&amp;C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drug and Unlicensed Biological Product\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your “Probiotics and Preterm Infants: Clinical Evidence” handout provided by your sales representative to hospital staff has a section with the heading “Probiotics in the NICU: Clinical Evidence” that states, “Probiotics have shown to significantly improve outcomes” for “All-cause mortality,” “Necrotizing enterocolitis (NEC),” “Late-onset sepsis,” and “Feeding tolerance,” and that represents “Benefits of probiotics on NEC,” as “significantly reduc[ing] incidence of NEC in clinical studies.” The other marketing handout with the heading “The Promise of Similac Another Innovation Only From Similac” states that Similac® Probiotic Supplement undergoes safety testing to “ensure the probiotic is ready for hospital use,” (emphasis omitted).\u003C\u002Fp>\n\n\u003Cp>Your website at www.pediatricproconnect.com (last visited in October 2023), includes a link to an Abbott infographic entitled “The Microbiome &amp; The Preterm Infant: Gut Immaturity &amp; Dysbiosis,” which states, “Importantly, giving probiotics to preterm infants can reduce the incidence of NEC.” As noted above, your www.abbottnutrition.com website and documents accessed from it further state that your product is available for “Hospitals and institutions,” and your Pediatric Product Nutrition Guide categorizes the product as for “Premature\u002F Low-Birth-Weight Infants.”\u003C\u002Fp>\n\n\u003Cp>Because these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&amp;C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\u003C\u002Fp>\n\n\u003Cp>Please be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&amp;C Act and the PHS Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Adulterated Dietary Supplement\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In addition to your Similac Probiotic Supplement being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Unsafe Food Additive: Bifidobacterium infantis (Bb-02)\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>Your Similac Probiotic Supplement is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(i)] because, when used in food for preterm infants,&nbsp;\u003Cem>B. infantis\u003C\u002Fem> (BB-02) is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&amp;C Act [21 U.S.C. §§321(s) and 348(a)].\u003C\u002Fp>\n\n\u003Cp>Food additives require premarket approval based on data demonstrating safety. Any substance added or intended for addition to food must have premarket approval by FDA as a food additive for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at section 201(s)(1)-(6) of the FD&amp;C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act [21 U.S.C. 342(a)(2)(C)(i)]. There is no food additive regulation that authorizes the use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02). In addition, as discussed below, we are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or in conventional foods, nor are we aware of a basis to conclude that any use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or otherwise in food for preterm infants is generally recognized as safe (GRAS).\u003C\u002Fp>\n\n\u003Cp>We are not aware of an applicable exception under section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] for the use of \u003Cem>B. infantis\u003C\u002Fem> (BB-02) in dietary supplements or in conventional foods. Section 201(s) of the FD&amp;C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. The label of your Similac Probiotic Supplement declares \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) as a dietary ingredient. However, the ingredient \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) does not meet the definition of a dietary ingredient. Under section 201(ff)(1) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) does not fall within any of these categories. Therefore, the ingredient \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) used in your product is a non-dietary ingredient added to a dietary supplement and must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\u003C\u002Fp>\n\n\u003Cp>We are not aware of a basis to conclude that any use of \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) in dietary supplements or food for preterm infants is GRAS. GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”), such as \u003Cem>B. infantis\u003C\u002Fem> (Bb-02), by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous&nbsp;subpopulation of varying ages (&lt;37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight &lt;1000 grams.”\u003C\u002Fp>\n\n\u003Cp>Although your Similac Probiotic Supplement label states that the product is “not intended for infants with compromised intestinal permeability,” and your Pediatric Product Nutrition Guide states that your product is “not intended for infants with intestinal permeability,” other marketing materials of yours directly contradict these statements. For example, your infographic titled, “How Probiotics Can Help My Preterm Infant, Infancy is an Important Time in Developing a Healthy Gut Microbiome,” acknowledges that the “[g]ut is not fully developed” in many preterm infants and nonetheless recommends your product be administered to this population because probiotics “increase the number of good bacteria in the gut, promoting a healthy microbiome.” Moreover, you categorize your product as a dietary supplement for premature\u002Flow-birth-weight infants in your Pediatric Product Nutrition Guide, and in your “Probiotics and Preterm Infants: Clinical Evidence” marketing handout that your sales representatives distribute to NICU dieticians, you have indicated that this product is designed specifically for preterm infants. Furthermore, statements on the product page of your website indicate your product is available for “Hospitals and institutions” and your “The Promise of Similac: Another Innovation Only From Similac” information sheet describes product testing to ensure it is “ready for hospital use.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is not GRAS for use in food for preterm infants. Because \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is not a dietary ingredient and is not GRAS or otherwise exempt from the food additive definition, and because your Similac Probiotic Supplement is intended to be added to food for preterm infants, your Similac Probiotic Tri-Blend product is adulterated under section 402(a)(2)(C)(i) of the FD&amp;C Act because \u003Cem>B. infantis\u003C\u002Fem> (Bb-02) is an unsafe food additive for use by premature infants within the meaning of sections 201(s) and 409 of the FD&amp;C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)].\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Section 402(f)(1)(B) Adulteration: Streptococcus thermophilus\u003C\u002Fem> (TH-4®)\u003C\u002Fp>\n\n\u003Cp>The label of your Similac Probiotic Supplement declares \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) as a dietary ingredient.\u003Cem> S. thermophilus\u003C\u002Fem> (TH-4®) is a dietary ingredient under section 201(ff)(1)(F) of the FD&amp;C Act [21 U.S.C. § 321(ff)(1)(F)]. \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) is also a new dietary ingredient under section 413(d) of the FD&amp;C Act [21 U.S.C. § 350b(d)], in that it is a dietary ingredient that was not marketed in the United States before October 15, 1994.\u003C\u002Fp>\n\n\u003Cp>A dietary supplement is adulterated under section 402(f)(1)(B) of the FD&amp;C Act if it contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. The available scientific information regarding the safety of S. thermophilus (TH-4®), when intended for consumption by preterm infants, indicates that there is inadequate information to provide reasonable assurance that \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®) does not present a significant or unreasonable risk of illness or injury. In fact, as noted above, available information on the use of microorganisms in products intended for preterm infants raises serious safety concerns. Therefore, your Similac Probiotic Supplement is an adulterated dietary supplement under section 402(f)(1)(B) of the FD&amp;C Act [21 U.S.C. § 342(f)(1)(B)] because it contains a new dietary ingredient, \u003Cem>S. thermophilus\u003C\u002Fem> (TH-4®), for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury when used in preterm infants. Introduction of this product into interstate commerce is prohibited under section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\u003C\u002Fp>\n\n\u003Cp>We advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your product in full compliance with the FD&amp;C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&amp;C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\u003C\u002Fp>\n\n\u003Cp>Within fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\u003C\u002Fp>\n\n\u003Cp>Your written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Melissa J. Mendoza\u003Cbr>\nDirector, Office of Compliance and Biologics Quality\u003Cbr>\nCenter for Biologics Evaluation and Research\u003C\u002Fp>\n\n\u003Cp>\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham\u003Cbr>\nDirector, Office of Compliance\u003Cbr>\nCenter for Food Safety and Applied Nutrition\u003C\u002Fp>\n\n\u003Cp>Cc:\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nBiologics\nDietary Supplements\nDrugs\n\nRecipient:\n\nRecipient Name\n\nRobert B. Ford\n\nRecipient Title\n\nCEO\n\nAbbott Laboratories\n\n100 Abbott Park Road\n\nAbbott Park, IL 60064\n\nUnited States\n\nrobert.ford@abbott.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\n\nDate: October 24, 2023\n\nWarning Letter #669353\n\nDear Mr. Ford:\n\nThis is to advise you that the United States Food and Drug Administration (FDA) has reviewed your company’s websites at www.abbottnutrition.com, www.abbott.com, and www.pediatricproconnect.com in October 2023 and your company’s marketing materials for Similac® Probiotic Tri-Blend (hereinafter Similac Probiotic Supplement or your product), which contains instructions on where to buy your product. The marketing materials FDA reviewed include one handout that bears the heading “Probiotics and Preterm Infants: Clinical Evidence” and another that bears the heading “The Promise of Similac Another Innovation Only From Similac,” which your sales representatives provided together to hospital staff. You refer to your product as a probiotic and offer it for sale to health care professionals in the United States. Your product is labeled as containing, among other ingredients, Bifidobacterium infantis (Bb-02) and Streptococcus thermophilus (TH-4®), otherwise known as B. infantis (Bb-02) and S. thermophilus (TH-4®), and you sell it for use in preterm infants.\n\nBased on the statements on your website and your marketing materials, your product is an unapproved new drug and unlicensed biological product that you introduced or delivered for introduction into interstate commerce in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 331(d)] and the Public Health Service Act (PHS Act) [42 U.S.C. § 262(a)(1)]. Your Similac Probiotic Supplement is also adulterated under section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)] because it contains B. infantis (Bb-02), an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act [21 U.S.C. §§321(s) and 348]; and S. thermophilus (TH-4®), a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury, when used in preterm infants. These violations are described in more detail below.\n\nAs explained further below, introducing or delivering your product for introduction into interstate commerce violates the FD&C Act and the PHS Act. You can find the FD&C Act, PHS Act, and FDA regulations through links on FDA’s home page at www.fda.gov.\n\nUnapproved New Drug and Unlicensed Biological Product\n\nYour “Probiotics and Preterm Infants: Clinical Evidence” handout provided by your sales representative to hospital staff has a section with the heading “Probiotics in the NICU: Clinical Evidence” that states, “Probiotics have shown to significantly improve outcomes” for “All-cause mortality,” “Necrotizing enterocolitis (NEC),” “Late-onset sepsis,” and “Feeding tolerance,” and that represents “Benefits of probiotics on NEC,” as “significantly reduc[ing] incidence of NEC in clinical studies.” The other marketing handout with the heading “The Promise of Similac Another Innovation Only From Similac” states that Similac® Probiotic Supplement undergoes safety testing to “ensure the probiotic is ready for hospital use,” (emphasis omitted).\n\nYour website at www.pediatricproconnect.com (last visited in October 2023), includes a link to an Abbott infographic entitled “The Microbiome & The Preterm Infant: Gut Immaturity & Dysbiosis,” which states, “Importantly, giving probiotics to preterm infants can reduce the incidence of NEC.” As noted above, your www.abbottnutrition.com website and documents accessed from it further state that your product is available for “Hospitals and institutions,” and your Pediatric Product Nutrition Guide categorizes the product as for “Premature\u002F Low-Birth-Weight Infants.”\n\nBecause these statements indicate that your product is intended for use in the mitigation, treatment, or prevention of disease, your product is a drug under section 201(g)(1)(B) of the FD&C Act [21 U.S.C. § 321(g)(1)(B)]. Additionally, your product is a biological product as defined in section 351(i) of the PHS Act [42 U.S.C. § 262(i)], because it is applicable to the prevention, treatment, or cure of a disease or condition of human beings.\n\nPlease be advised that to lawfully market a drug that is also a biological product, a valid biologics license application (BLA) must be in effect [42 U.S.C. § 262(a)]. Such licenses are issued only after a demonstration that the product is safe, pure, and potent. While in the development stage, such products may be distributed for clinical use in humans only if the sponsor has an investigational new drug application (IND) in effect as specified by FDA regulations (21 U.S.C. § 355(i); 42 U.S.C. § 262(a)(3); 21 CFR Part 312). Your product is not the subject of an approved BLA nor is there an IND in effect for its use. Based on this information, your actions have violated the FD&C Act and the PHS Act.\n\nAdulterated Dietary Supplement\n\nIn addition to your Similac Probiotic Supplement being an unapproved new drug and unlicensed biological product, your product is adulterated within the meaning of section 402(a)(2)(C)(i) and (f)(1)(B) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i) and (f)(1)(B)].\n\nUnsafe Food Additive: Bifidobacterium infantis (Bb-02)\n\nYour Similac Probiotic Supplement is adulterated within the meaning of section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(i)] because, when used in food for preterm infants, B. infantis (BB-02) is an unsafe food additive within the meaning of sections 201(s) and 409(a) of the FD&C Act [21 U.S.C. §§321(s) and 348(a)].\n\nFood additives require premarket approval based on data demonstrating safety. Any substance added or intended for addition to food must have premarket approval by FDA as a food additive for that use unless the use is generally recognized as safe (GRAS) by qualified experts or meets one of the listed exceptions at section 201(s)(1)-(6) of the FD&C Act [21 U.S.C. § 321(s)(1)-(6)]. Otherwise, the substance is deemed an unsafe food additive, and food that is or contains an unsafe food additive is adulterated under section 402(a)(2)(C)(i) of the FD&C Act [21 U.S.C. 342(a)(2)(C)(i)]. There is no food additive regulation that authorizes the use of B. infantis (Bb-02). In addition, as discussed below, we are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. infantis (Bb-02) in dietary supplements or in conventional foods, nor are we aware of a basis to conclude that any use of B. infantis (Bb-02) in dietary supplements or otherwise in food for preterm infants is generally recognized as safe (GRAS).\n\nWe are not aware of an applicable exception under section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] for the use of B. infantis (BB-02) in dietary supplements or in conventional foods. Section 201(s) of the FD&C Act [21 U.S.C. § 321(s)] exempts dietary ingredients used in dietary supplements from the food additive definition. However, non-dietary ingredients intended for use in dietary supplements are not exempt from the food additive definition and must meet the same requirements as substances added to conventional foods. The label of your Similac Probiotic Supplement declares B. infantis (Bb-02) as a dietary ingredient. However, the ingredient B. infantis (Bb-02) does not meet the definition of a dietary ingredient. Under section 201(ff)(1) of the FD&C Act [21 U.S.C. § 321(ff)(1)], a dietary ingredient is a vitamin; a mineral; an herb or other botanical; an amino acid; a dietary substance for use by man to supplement the diet by increasing the total dietary intake; or a concentrate, metabolite, constituent, extract, or combination of any dietary ingredient from the preceding categories. B. infantis (Bb-02) does not fall within any of these categories. Therefore, the ingredient B. infantis (Bb-02) used in your product is a non-dietary ingredient added to a dietary supplement and must be used in accordance with a food additive regulation or be GRAS for its intended use, unless it qualifies for another exception to the food additive definition.\n\nWe are not aware of a basis to conclude that any use of B. infantis (Bb-02) in dietary supplements or food for preterm infants is GRAS. GRAS status requires publicly available evidence that the intended use is safe and a consensus among qualified experts that the intended use is safe (21 CFR 170.30). The information on the use of living microorganisms (also referred to as “probiotics”), such as B. infantis (Bb-02), by preterm infants in the scientific literature raises serious safety concerns. Preterm infants are a highly susceptible, heterogenous subpopulation of varying ages (\u003C37 weeks of gestation) and weight, who are physiologically, developmentally, and metabolically immature compared to healthy term infants, resulting in their having a high risk for morbidity and mortality and requiring specialized care; thus, we have greater safety concerns for this population than we have for a healthy term infant population. Because their gastrointestinal system is not fully matured, preterm infants have more permeable intestinal linings, often referred to as “leaky guts,” and motility problems, which can lead to opportunistic infections and sepsis when ingesting living microorganisms. The current published literature does not show consensus among qualified experts that the use of living microorganisms in preterm infants is safe. For example, the American Academy of Pediatrics does not endorse the routine use of living microorganisms in preterm infants, finding conflicting data on its safety and efficacy in this vulnerable population, particularly those with birth weight \u003C1000 grams.”\n\nAlthough your Similac Probiotic Supplement label states that the product is “not intended for infants with compromised intestinal permeability,” and your Pediatric Product Nutrition Guide states that your product is “not intended for infants with intestinal permeability,” other marketing materials of yours directly contradict these statements. For example, your infographic titled, “How Probiotics Can Help My Preterm Infant, Infancy is an Important Time in Developing a Healthy Gut Microbiome,” acknowledges that the “[g]ut is not fully developed” in many preterm infants and nonetheless recommends your product be administered to this population because probiotics “increase the number of good bacteria in the gut, promoting a healthy microbiome.” Moreover, you categorize your product as a dietary supplement for premature\u002Flow-birth-weight infants in your Pediatric Product Nutrition Guide, and in your “Probiotics and Preterm Infants: Clinical Evidence” marketing handout that your sales representatives distribute to NICU dieticians, you have indicated that this product is designed specifically for preterm infants. Furthermore, statements on the product page of your website indicate your product is available for “Hospitals and institutions” and your “The Promise of Similac: Another Innovation Only From Similac” information sheet describes product testing to ensure it is “ready for hospital use.” The care of infants in a healthcare setting includes care of preterm infants; therefore, this use is further evidence of the intended use of this product for consumption by preterm infants.\n\nB. infantis (Bb-02) is not GRAS for use in food for preterm infants. Because B. infantis (Bb-02) is not a dietary ingredient and is not GRAS or otherwise exempt from the food additive definition, and because your Similac Probiotic Supplement is intended to be added to food for preterm infants, your Similac Probiotic Tri-Blend product is adulterated under section 402(a)(2)(C)(i) of the FD&C Act because B. infantis (Bb-02) is an unsafe food additive for use by premature infants within the meaning of sections 201(s) and 409 of the FD&C Act [21 U.S.C. §§ 321(s) and 348]. The introduction or delivery for introduction into interstate commerce of any food that is adulterated is a prohibited act under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)].\n\nSection 402(f)(1)(B) Adulteration: Streptococcus thermophilus (TH-4®)\n\nThe label of your Similac Probiotic Supplement declares S. thermophilus (TH-4®) as a dietary ingredient. S. thermophilus (TH-4®) is a dietary ingredient under section 201(ff)(1)(F) of the FD&C Act [21 U.S.C. § 321(ff)(1)(F)]. S. thermophilus (TH-4®) is also a new dietary ingredient under section 413(d) of the FD&C Act [21 U.S.C. § 350b(d)], in that it is a dietary ingredient that was not marketed in the United States before October 15, 1994.\n\nA dietary supplement is adulterated under section 402(f)(1)(B) of the FD&C Act if it contains a new dietary ingredient for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury. The available scientific information regarding the safety of S. thermophilus (TH-4®), when intended for consumption by preterm infants, indicates that there is inadequate information to provide reasonable assurance that S. thermophilus (TH-4®) does not present a significant or unreasonable risk of illness or injury. In fact, as noted above, available information on the use of microorganisms in products intended for preterm infants raises serious safety concerns. Therefore, your Similac Probiotic Supplement is an adulterated dietary supplement under section 402(f)(1)(B) of the FD&C Act [21 U.S.C. § 342(f)(1)(B)] because it contains a new dietary ingredient, S. thermophilus (TH-4®), for which there is inadequate information to provide reasonable assurance that such ingredient does not present a significant or unreasonable risk of illness or injury when used in preterm infants. Introduction of this product into interstate commerce is prohibited under section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. The violations cited in this letter are not meant to be an all-inclusive list of violations that may exist in connection with your products. You are responsible for promptly investigating and determining the causes of any violations, correcting them, and preventing their recurrence, and ensuring full compliance with the law.\n\nWe advise you to comprehensively review your website, product labels, and other labeling and marketing materials to ensure that you are lawfully marketing your product in full compliance with the FD&C Act, the PHS Act, and their implementing regulations. Failure to adequately address this matter may result in enforcement action without further notice, including, without limitation, seizure and\u002For injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. If you believe that your product is not in violation of the FD&C Act and the PHS Act, include your reasoning and any supporting information for our consideration in your response to this letter.\n\nWithin fifteen working days of receipt of this letter, please notify FDA in writing of the specific steps that you have taken to correct any violations. Your response should include an explanation of each step being taken to prevent the recurrence of violations as well as related documentation. If you cannot complete all corrective actions within fifteen working days, state the reason for the delay and the date by which you will complete the correction.\n\nYour written response should be sent to the following address: U.S. Food and Drug Administration, Center for Biologics Evaluation and Research, Document Control Center, 10903 New Hampshire Avenue, WO71-G112, Silver Spring, MD 20993-0002. Please also email your response to CBERDCMRecommendations@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMelissa J. Mendoza\n\nDirector, Office of Compliance and Biologics Quality\n\nCenter for Biologics Evaluation and Research\n\n\u002FS\u002F\n\nAnn M. Oxenham\n\nDirector, Office of Compliance\n\nCenter for Food Safety and Applied Nutrition\n\nCc:\n\n(b)(4)","Abbott Laboratories","abbott-laboratories-669353-10242023","2026-08-18T06:42:28.994808+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-laboratories-669353-10242023","2026-10-26T08:07:48.691438+00:00","Warning Letter","Closed Out","2023-10-25","669353","BiologicsDietary SupplementsDrugs","2025-01-21","Robert B. Ford","2026-08-20T00:34:47.53+00:00","VIA UPS and Electronic Mail","2023-10-24",{"id":35,"raw":36,"subject":41,"body_html":42,"body_text":43,"firm_name":44,"letter_id":45,"created_at":46,"fei_number":21,"letter_url":47,"updated_at":48,"action_type":24,"case_status":49,"posted_date":50,"marcs_cms_no":51,"product_type":52,"closeout_date":21,"issuing_office":40,"recipient_name":53,"body_fetched_at":54,"delivery_method":55,"recipient_title":21,"reference_number":21,"action_taken_date":56,"medical_device_id":21,"response_letter_date":21},354,[37,38,39,40,41,13,13,13],"\u003Ctime datetime=\"2026-02-03T05:00:00Z\">02\u002F03\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-01-23T05:00:00Z\">01\u002F23\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-diabetes-care-inc-722046-01232026\">Abbott Diabetes Care, Inc. \u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Christopher Scoggins\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Executive Vice President of Diabetes Care \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abbott Diabetes Care, Inc. \u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1360 S Loop Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Alameda\u003C\u002Fspan>, \u003Cspan>CA\u003C\u002Fspan> \u003Cspan>94502-7000\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:(b)(4)\"> (b)(4)\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>CMS # 722046\u003C\u002Fp>\u003Cp>January 23, 2026\u003C\u002Fp>\u003Cp>Dear Mr. Scoggins:\u003C\u002Fp>\u003Cp>During an inspection of your firm located at 1360 S. Loop Rd, Alameda, CA 94502-7000, FEI #3002803444, on October 14, 2025, through October 23, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures FreeStyle Libre Flash and Continuous Glucose Monitoring Systems including the FreeStyle Libre 3. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\u003Cp>\u003Cu>Quality System Regulation Violations\u003C\u002Fu>\u003C\u002Fp>\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations\u003C\u002Fu> (CFR), Part 820.\u003C\u002Fp>\u003Cp>We received your firm’s responses dated November 14, 2025, and December 19, 2025, from Christopher Scoggins and Denise Reid concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on October 23, 2025. These violations include but are not limited to the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures to ensure that the device design is correctly translated into production specifications, as required by 21 CFR § 820.30(h).\u003C\u002Fp>\u003Cp>For example, your firm has not established and maintained procedures for design transfer of your Project \u003Cstrong>(b)(4) \u003C\u002Fstrong>(FreeStyle Libre 3), specifically regarding transfer of performance specifications to third-party manufacturers. Your design transfer process did not ensure that performance specifications established in DOC40918 were translated into manufacturing specifications for your third-party manufacturer.\u003C\u002Fp>\u003Cp>Your System Design Requirements, \u003Cstrong>(b)(4)\u003C\u002Fstrong> DOC40918 Rev. S, dated September 26, 2025, identifies sensor glucose accuracy performance requirements, including:\u003C\u002Fp>\u003Cul>\u003Cli>At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> of sensor glucose results within ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> or \u003Cstrong>(b)(4)\u003C\u002Fstrong> of reference\u003C\u002Fli>\u003Cli>At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> within ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> of reference for adult population\u003C\u002Fli>\u003Cli>At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> within ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> or ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> of reference\u003C\u002Fli>\u003Cli>At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> within ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> or ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> of reference for adult population\u003C\u002Fli>\u003Cli>At least \u003Cstrong>(b)(4)\u003C\u002Fstrong> within ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> or ±\u003Cstrong>(b)(4)\u003C\u002Fstrong> of reference for adult population\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm established these requirements to comply with 21 CFR 862.1355 but did not transfer these specifications to your third-party manufacturer or ensure ongoing monitoring of in-process and finished product. Your firm failed to meet 21 CFR 862.1355(b)(3) special controls requirement that states: \"design verification and validation must include adequate controls established during manufacturing and at product release to ensure the released product meets the performance specifications.\" No controls were established at final product release to ensure finished products meet performance specifications.\u003C\u002Fp>\u003Cp>Additionally, DOC42469, Design Transfer Plan, Rev. D, does not describe how accuracy performance specifications derived from iCGM special controls are flowed down to external manufacturing sites or incorporated into their acceptance procedures. Contract manufacturers responsible for final assembly and release were not provided with accuracy performance requirements and were not required to verify finished-device accuracy performance prior to release.\u003C\u002Fp>\u003Cp>We reviewed your firm's November 14, 2025, response and conclude it is not adequate. Your response does not identify whether finished-device accuracy performance release testing will be performed by Abbott or contract manufacturers, nor where these requirements are documented within the Device Master Record (DMR). Your Sensor Manufacturing Process Monitoring lacks: (1) specific performance specifications for glucose clinical accuracy; (2) direct linkage to the accuracy performance requirements at product release; and (3) adequate procedures to detect sensors that could produce erroneous glucose results. Your monitoring documents focus on general manufacturing parameters, biocontamination control, and facility requirements but inadequately address sensor glucose accuracy performance requirements. Your responsive attachments fail to demonstrate how the specific accuracy thresholds (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are translated into component-level specifications or systematically translated through all levels of manufacturing control.\u003C\u002Fp>\u003Cp>We reviewed your firm's December 19, 2025, response and conclude it is not adequate. Although procedural updates were described, your firm did not provide objective evidence demonstrating that accuracy performance requirements have been fully transferred into production specifications, incorporated into the DMR, and implemented as acceptance procedures by manufacturing entities responsible for final assembly and release. Your response addresses Bluetooth (BLE) connectivity testing for FreeStyle Libre 2 rather than glucose accuracy performance for \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The attachment implements interim sampling and testing but doesn't address design transfer procedure inadequacies. Your firm monitors BLE functionality by \u003Cstrong>(b)(4)\u003C\u002Fstrong> samples \u003Cstrong>(b)(4)\u003C\u002Fstrong>, but there is no evidence this correlates with glucose accuracy performance. The attachments contain extensive sampling protocols but do not demonstrate how glucose accuracy performance requirements (±\u003Cstrong>(b)(4)\u003C\u002Fstrong>, ±\u003Cstrong>(b)(4)\u003C\u002Fstrong>) are translated into component specifications in the Bill of Materials (BOM) or provide evidence of updates to design transfer procedures and revised component specifications. Additional testing (PCT and BLE) has been implemented but is not formally documented in design transfer documentation (DOC42469 and DOC42066), and there is no evidence of systematic review\u002Frevision of existing design transfer procedures (7.3W04). The new testing procedures lack sufficient detail on how they will detect sensors that could produce erroneous results due to causes in DOC40952-001.Although interim actions are implemented, permanent solutions such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> won’t be operational until \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This creates a \u003Cstrong>(b)(4)\u003C\u002Fstrong> gap where you appear to rely primarily on enhanced monitoring rather than systematic design transfer controls.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>For example, our inspection revealed that your firm releases finished FreeStyle Libre integrated continuous glucose monitoring system (iCGM) devices without performance-testing the finished, fully assembled, sterilized, programmed, and packaged devices for accuracy prior to distribution. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> is performed only on unassembled sensor tails, prior to final assembly, \u003Cstrong>(b)(4)\u003C\u002Fstrong> sterilization, programming, packaging, and distribution. During the inspection, your firm’s management confirmed that finished devices are not performance-tested for accuracy at product release.\u003C\u002Fp>\u003Cp>The iCGM special controls require that manufacturing and product release controls be established to ensure that released devices meet validated accuracy performance requirements (21 CFR 862.1355(b)(3)). Reliance on upstream, component-level testing performed prior to critical manufacturing steps does not ensure that finished, sterilized, and packaged devices meet accuracy performance requirements at the time of release. In addition, inspectional evidence documents that contract manufacturers responsible for final assembly and release were not provided accuracy performance specifications and were not required to verify finished-device accuracy performance prior to release. As a result, your firm has not established final acceptance activities to ensure that only conforming finished devices that meet the accuracy performance requirements are distributed, as required by 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>Your firm’s responses dated November 14, 2025, and December 19, 2025, describe interim inspections, enhanced monitoring activities, and proposed future implementation of \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude they are not adequate. The interim inspections and monitoring activities described are temporary, are not validated as manufacturing or release controls, and do not ensure that finished devices released to distribution meet validated accuracy performance requirements at the time of release. In addition, the proposed finished-device accuracy release testing has not been implemented and does not demonstrate that devices already release to distribution conform to validated accuracy performance requirements. Additionally, your response states you will continue to rely on the \u003Cstrong>(b)(4)\u003C\u002Fstrong> test for part of your acceptance activities, however, as noted below, we do not agree this test has been properly validated. Therefore, your firm has not established adequate manufacturing and product release controls to ensure compliance with 21 CFR 862.1355(b)(3) and 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain procedures, where appropriate, for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\u003C\u002Fp>\u003Cp>For example, our inspection revealed that your firm failed to establish statistically valid acceptance criteria and sampling plans to ensure that only conforming finished devices are released to distribution. DOC42012, Rev. B, Section 9.1 (pp. 5-7) states that an observed in-vivo precision value of approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> CV was decomposed into equal between-subject and between-sensor components, resulting in an estimated between-sensor CV of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which was then used to derive \u003Cstrong>(b)(4)\u003C\u002Fstrong> precision acceptance limits.\u003C\u002Fp>\u003Cp>The clinical performance monitoring study used to support this composition (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) does not permit separation of manufacturing-related sensor variability from subject-related, physiological, behavioral, and reference-method variability because \u003Cstrong>(b)(4)\u003C\u002Fstrong>. As a result, the observed in-vivo variability reflects a conflation of uncontrolled sources, and no objective evidence was provided demonstrating that subject-related and sensor-related variance components can be reliably partitioned using this study design.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude they are not adequate. Your response dated November 14, 2025, Table 1: Summary of Product Release Testing (pp. 4-5), proposes sampling plans for finished-device precision testing, deployment testing, BLE communication testing, and programming verification without providing statistical justification, such as confidence levels, power analyses, assumed defect rates, or risk-based rationale, as required by 21 CFR 820.250(a). Your response further proposes \u003Cstrong>(b)(4)\u003C\u002Fstrong> to \u003Cstrong>(b)(4)\u003C\u002Fstrong> without demonstrating that the sample size is adequate to detect failures associated with distinct failure modes.\u003C\u002Fp>\u003Cp>Your firm has not established statistically valid acceptance criteria or sampling plans and has not provided objective evidence demonstrating that proposed sampling strategies are sufficient to ensure detection of nonconforming finished devices. Therefore, FDA lacks assurance that final acceptance activities are adequate to ensure that only conforming finished devices are released, as required by 21 CR 820.250(a) and 21 CFR 820.80(d).\u003C\u002Fp>\u003Cp>4. Failure to adequately establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>For example, although the FreeStyle Libre iCGM previously demonstrated compliance with accuracy performance requirements during premarket review, the inspection revealed that your firm failed to adequately validate that the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as implemented, is an appropriate manufacturing and release control to ensure preservation of that validated performance.\u003C\u002Fp>\u003Cp>Specifically, DOC42012, Rev. B, Section 9.1 (pp. 5-7) states that \u003Cstrong>(b)(4)\u003C\u002Fstrong> specifications were derived from the post-market performance monitoring study \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which uses \u003Cstrong>(b)(4)\u003C\u002Fstrong> measurements as the reference method. However, the iCGM special controls require that accuracy performance be ensured using an FDA-accepted laboratory reference method that is precise, accurate, and traceable to a higher-order reference (21 CFR 862.1355(b)(1)(ii)).\u003C\u002Fp>\u003Cp>In addition, DOC42012, Rev. B, Table 2 (pp. 6-7) describes attempts to convert \u003Cstrong>(b)(4)\u003C\u002Fstrong> accuracy results to \u003Cstrong>(b)(4)\u003C\u002Fstrong> accuracy using \u003Cstrong>(b)(4)\u003C\u002Fstrong> derived from comparisons between studies with fundamentally different designs, subject populations, and reference methods. Further DOC42012, Rev. B, Sections 9.1.2-9.1.5 and Section 10 (pp. 12-18) assert equivalence between \u003Cstrong>(b)(4)\u003C\u002Fstrong> confidence intervals and the one-sided 95% lower confidence bounds required by regulation, despite evidence that the underlying error distributions violate the assumptions necessary for such substitution. The iCGM Sensor Lot Release Specification Summary Memo dated October 21, 2025, further documents use of a weighted composite ±\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u002F±\u003Cstrong>(b)(4)\u003C\u002Fstrong> accuracy requirement than independent evaluation of each required glucose range.\u003C\u002Fp>\u003Cp>We reviewed your firm’s responses and conclude that they are not adequate. The interim monitoring activities and proposed future testing do not provide objective evidence validating \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as currently implemented, as a manufacturing or release control capable of ensuring that finished devices continue to meet validated accuracy performance requirements. Therefore, your firm has not adequately validated its manufacturing and release controls, as required by 21 CFR 820.30(g) and 21 CFR 862.1355(b)(3).\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 722046” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Raymond W. Brullo, via email at raymond.brullo@fda.hhs.gov\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\u003Cp>cc: Ms. Denise Reid, Divisional Vice President Quality Assurance &amp; Compliance\u003Cbr>denise.reid@abbott.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nChristopher Scoggins\n\nRecipient Title\n\nExecutive Vice President of Diabetes Care\n\nAbbott Diabetes Care, Inc.\n\n1360 S Loop Rd\n\nAlameda, CA 94502-7000\n\nUnited States\n\n(b)(4)\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 722046\nJanuary 23, 2026\nDear Mr. Scoggins:\nDuring an inspection of your firm located at 1360 S. Loop Rd, Alameda, CA 94502-7000, FEI #3002803444, on October 14, 2025, through October 23, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures FreeStyle Libre Flash and Continuous Glucose Monitoring Systems including the FreeStyle Libre 3. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\nQuality System Regulation Violations\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\nWe received your firm’s responses dated November 14, 2025, and December 19, 2025, from Christopher Scoggins and Denise Reid concerning our investigator’s observations noted on the Form FDA 483, List of Inspectional Observations (FDA 483) that was issued to your firm on October 23, 2025. These violations include but are not limited to the following:\n1. Failure to adequately establish and maintain procedures to ensure that the device design is correctly translated into production specifications, as required by 21 CFR § 820.30(h).\nFor example, your firm has not established and maintained procedures for design transfer of your Project (b)(4) (FreeStyle Libre 3), specifically regarding transfer of performance specifications to third-party manufacturers. Your design transfer process did not ensure that performance specifications established in DOC40918 were translated into manufacturing specifications for your third-party manufacturer.\nYour System Design Requirements, (b)(4) DOC40918 Rev. S, dated September 26, 2025, identifies sensor glucose accuracy performance requirements, including:\nAt least (b)(4) of sensor glucose results within ±(b)(4) or (b)(4) of reference\nAt least (b)(4) within ±(b)(4) of reference for adult population\nAt least (b)(4) within ±(b)(4) or ±(b)(4) of reference\nAt least (b)(4) within ±(b)(4) or ±(b)(4) of reference for adult population\nAt least (b)(4) within ±(b)(4) or ±(b)(4) of reference for adult population\nYour firm established these requirements to comply with 21 CFR 862.1355 but did not transfer these specifications to your third-party manufacturer or ensure ongoing monitoring of in-process and finished product. Your firm failed to meet 21 CFR 862.1355(b)(3) special controls requirement that states: \"design verification and validation must include adequate controls established during manufacturing and at product release to ensure the released product meets the performance specifications.\" No controls were established at final product release to ensure finished products meet performance specifications.\nAdditionally, DOC42469, Design Transfer Plan, Rev. D, does not describe how accuracy performance specifications derived from iCGM special controls are flowed down to external manufacturing sites or incorporated into their acceptance procedures. Contract manufacturers responsible for final assembly and release were not provided with accuracy performance requirements and were not required to verify finished-device accuracy performance prior to release.\nWe reviewed your firm's November 14, 2025, response and conclude it is not adequate. Your response does not identify whether finished-device accuracy performance release testing will be performed by Abbott or contract manufacturers, nor where these requirements are documented within the Device Master Record (DMR). Your Sensor Manufacturing Process Monitoring lacks: (1) specific performance specifications for glucose clinical accuracy; (2) direct linkage to the accuracy performance requirements at product release; and (3) adequate procedures to detect sensors that could produce erroneous glucose results. Your monitoring documents focus on general manufacturing parameters, biocontamination control, and facility requirements but inadequately address sensor glucose accuracy performance requirements. Your responsive attachments fail to demonstrate how the specific accuracy thresholds ((b)(4)) are translated into component-level specifications or systematically translated through all levels of manufacturing control.\nWe reviewed your firm's December 19, 2025, response and conclude it is not adequate. Although procedural updates were described, your firm did not provide objective evidence demonstrating that accuracy performance requirements have been fully transferred into production specifications, incorporated into the DMR, and implemented as acceptance procedures by manufacturing entities responsible for final assembly and release. Your response addresses Bluetooth (BLE) connectivity testing for FreeStyle Libre 2 rather than glucose accuracy performance for (b)(4). The attachment implements interim sampling and testing but doesn't address design transfer procedure inadequacies. Your firm monitors BLE functionality by (b)(4) samples (b)(4), but there is no evidence this correlates with glucose accuracy performance. The attachments contain extensive sampling protocols but do not demonstrate how glucose accuracy performance requirements (±(b)(4), ±(b)(4)) are translated into component specifications in the Bill of Materials (BOM) or provide evidence of updates to design transfer procedures and revised component specifications. Additional testing (PCT and BLE) has been implemented but is not formally documented in design transfer documentation (DOC42469 and DOC42066), and there is no evidence of systematic review\u002Frevision of existing design transfer procedures (7.3W04). The new testing procedures lack sufficient detail on how they will detect sensors that could produce erroneous results due to causes in DOC40952-001.Although interim actions are implemented, permanent solutions such as (b)(4) won’t be operational until (b)(4). This creates a (b)(4) gap where you appear to rely primarily on enhanced monitoring rather than systematic design transfer controls.\n2. Failure to adequately establish and maintain procedures for finished device acceptance to ensure that each production run, lot, or batch of finished devices meets acceptance criteria, as required by 21 CFR 820.80(d).\nFor example, our inspection revealed that your firm releases finished FreeStyle Libre integrated continuous glucose monitoring system (iCGM) devices without performance-testing the finished, fully assembled, sterilized, programmed, and packaged devices for accuracy prior to distribution. The (b)(4) is performed only on unassembled sensor tails, prior to final assembly, (b)(4) sterilization, programming, packaging, and distribution. During the inspection, your firm’s management confirmed that finished devices are not performance-tested for accuracy at product release.\nThe iCGM special controls require that manufacturing and product release controls be established to ensure that released devices meet validated accuracy performance requirements (21 CFR 862.1355(b)(3)). Reliance on upstream, component-level testing performed prior to critical manufacturing steps does not ensure that finished, sterilized, and packaged devices meet accuracy performance requirements at the time of release. In addition, inspectional evidence documents that contract manufacturers responsible for final assembly and release were not provided accuracy performance specifications and were not required to verify finished-device accuracy performance prior to release. As a result, your firm has not established final acceptance activities to ensure that only conforming finished devices that meet the accuracy performance requirements are distributed, as required by 21 CFR 820.80(d).\nYour firm’s responses dated November 14, 2025, and December 19, 2025, describe interim inspections, enhanced monitoring activities, and proposed future implementation of (b)(4).\nWe reviewed your firm’s responses and conclude they are not adequate. The interim inspections and monitoring activities described are temporary, are not validated as manufacturing or release controls, and do not ensure that finished devices released to distribution meet validated accuracy performance requirements at the time of release. In addition, the proposed finished-device accuracy release testing has not been implemented and does not demonstrate that devices already release to distribution conform to validated accuracy performance requirements. Additionally, your response states you will continue to rely on the (b)(4) test for part of your acceptance activities, however, as noted below, we do not agree this test has been properly validated. Therefore, your firm has not established adequate manufacturing and product release controls to ensure compliance with 21 CFR 862.1355(b)(3) and 21 CFR 820.80(d).\n3. Failure to adequately establish and maintain procedures, where appropriate, for identifying valid statistical techniques required for establishing, controlling, and verifying the acceptability of process capability and product characteristics, as required by 21 CFR 820.250(a).\nFor example, our inspection revealed that your firm failed to establish statistically valid acceptance criteria and sampling plans to ensure that only conforming finished devices are released to distribution. DOC42012, Rev. B, Section 9.1 (pp. 5-7) states that an observed in-vivo precision value of approximately (b)(4) CV was decomposed into equal between-subject and between-sensor components, resulting in an estimated between-sensor CV of (b)(4), which was then used to derive (b)(4) precision acceptance limits.\nThe clinical performance monitoring study used to support this composition ((b)(4)) does not permit separation of manufacturing-related sensor variability from subject-related, physiological, behavioral, and reference-method variability because (b)(4). As a result, the observed in-vivo variability reflects a conflation of uncontrolled sources, and no objective evidence was provided demonstrating that subject-related and sensor-related variance components can be reliably partitioned using this study design.\nWe reviewed your firm’s responses and conclude they are not adequate. Your response dated November 14, 2025, Table 1: Summary of Product Release Testing (pp. 4-5), proposes sampling plans for finished-device precision testing, deployment testing, BLE communication testing, and programming verification without providing statistical justification, such as confidence levels, power analyses, assumed defect rates, or risk-based rationale, as required by 21 CFR 820.250(a). Your response further proposes (b)(4) to (b)(4) without demonstrating that the sample size is adequate to detect failures associated with distinct failure modes.\nYour firm has not established statistically valid acceptance criteria or sampling plans and has not provided objective evidence demonstrating that proposed sampling strategies are sufficient to ensure detection of nonconforming finished devices. Therefore, FDA lacks assurance that final acceptance activities are adequate to ensure that only conforming finished devices are released, as required by 21 CR 820.250(a) and 21 CFR 820.80(d).\n4. Failure to adequately establish and maintain design validation procedures to ensure that devices conform to defined user needs and intended uses and shall include testing of production units under actual or simulated use conditions, as required by 21 CFR 820.30(g).\nFor example, although the FreeStyle Libre iCGM previously demonstrated compliance with accuracy performance requirements during premarket review, the inspection revealed that your firm failed to adequately validate that the (b)(4), as implemented, is an appropriate manufacturing and release control to ensure preservation of that validated performance.\nSpecifically, DOC42012, Rev. B, Section 9.1 (pp. 5-7) states that (b)(4) specifications were derived from the post-market performance monitoring study (b)(4), which uses (b)(4) measurements as the reference method. However, the iCGM special controls require that accuracy performance be ensured using an FDA-accepted laboratory reference method that is precise, accurate, and traceable to a higher-order reference (21 CFR 862.1355(b)(1)(ii)).\nIn addition, DOC42012, Rev. B, Table 2 (pp. 6-7) describes attempts to convert (b)(4) accuracy results to (b)(4) accuracy using (b)(4) derived from comparisons between studies with fundamentally different designs, subject populations, and reference methods. Further DOC42012, Rev. B, Sections 9.1.2-9.1.5 and Section 10 (pp. 12-18) assert equivalence between (b)(4) confidence intervals and the one-sided 95% lower confidence bounds required by regulation, despite evidence that the underlying error distributions violate the assumptions necessary for such substitution. The iCGM Sensor Lot Release Specification Summary Memo dated October 21, 2025, further documents use of a weighted composite ±(b)(4)\u002F±(b)(4) accuracy requirement than independent evaluation of each required glucose range.\nWe reviewed your firm’s responses and conclude that they are not adequate. The interim monitoring activities and proposed future testing do not provide objective evidence validating (b)(4), as currently implemented, as a manufacturing or release control capable of ensuring that finished devices continue to meet validated accuracy performance requirements. Therefore, your firm has not adequately validated its manufacturing and release controls, as required by 21 CFR 820.30(g) and 21 CFR 862.1355(b)(3).\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties. Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent via email to Establishment Assessment Team 3 Acting Assistant Director, Jeffrey Wooley, at CDRHEnforcement@fda.hhs.gov. Please include in the subject line, “CMS Case 722046” when replying. If you have any questions about the contents of this letter, please contact: Compliance Officer, Raymond W. Brullo, via email at raymond.brullo@fda.hhs.gov\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of the violations and take prompt actions to correct the violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health\ncc: Ms. Denise Reid, Divisional Vice President Quality Assurance & Compliance\ndenise.reid@abbott.com","Abbott Diabetes Care, Inc.","abbott-diabetes-care-inc-722046-01232026","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-diabetes-care-inc-722046-01232026","2026-10-26T08:07:48.629192+00:00","Issued","2026-02-03","722046","Medical Devices","Christopher Scoggins","2026-08-19T05:07:25.839+00:00","VIA Electronic Mail","2026-01-23",{"id":58,"raw":59,"subject":63,"body_html":64,"body_text":65,"firm_name":66,"letter_id":67,"created_at":68,"fei_number":21,"letter_url":69,"updated_at":70,"action_type":24,"case_status":49,"posted_date":71,"marcs_cms_no":72,"product_type":52,"closeout_date":21,"issuing_office":40,"recipient_name":73,"body_fetched_at":74,"delivery_method":55,"recipient_title":21,"reference_number":21,"action_taken_date":75,"medical_device_id":21,"response_letter_date":21},2126,[60,61,62,40,63,13,13,13],"\u003Ctime datetime=\"2023-04-19T01:20:00Z\">04\u002F18\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2022-11-08T05:00:00Z\">11\u002F08\u002F2022\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-point-care-canada-limited-640946-11082022\">Abbott Point of Care Canada Limited\u003C\u002Fa>","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Edward O’Neill\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Divisional Vice President, Manufacturing Operations\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Abbott Point of Care Canada Limited\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>185 Corkstown Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Nepean\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>K2H 8V4\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Ted.oneill@abbott.com\"> Ted.oneill@abbott.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>November 8, 2022\u003Cbr>\n\u003Cbr>\nDear Edward O’Neill:\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Ottawa, Canada on May 16, 2022, through May 19, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the i-STAT cTnI Test intended for the quantitative measurement of&nbsp;cardiac troponin I in whole blood or plasma. These measurements are intended to be used in the diagnosis and treatment of myocardial infarction and as an aid in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that the i-STAT cTnI cartridges are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g), 21 U.S.C. § 360j(g), for this device. This device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify FDA of its intent to introduce the devices into commercial distribution in a notice or other information respecting modifications to these devices was not provided to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\u003C\u002Fp>\n\n\u003Cp>Your firm’s i-STAT cTnI Test was originally cleared for use with heparinized whole blood and plasma in K031739 and cleared for use with whole blood (not heparinized) in K051433. However, you have made multiple significant design changes to the i-STAT cTnI cartridge since 2003. For example:\u003C\u002Fp>\n\n\u003Cp>1. Your firm implemented change \u003Cstrong>(b)(4)\u003C\u002Fstrong> \"Alternate source of \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" (effective: 05- May-2022) to update the material specification (\u003Cstrong>(b)(4)\u003C\u002Fstrong>) of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> which is obtained from Sigma and used as an Interferent Eliminating Proteins (IEP) in the immune base prints. This supplier part number change was due to a process change that replaces monoclonal antibody production in live \u003Cstrong>(b)(4)\u003C\u002Fstrong> with production in cell culture. The alternate source of IgM that was used to reduce interference could have a direct impact on device performance due to different interference relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and therefore, requires submission of a new premarket notification (510(k)).\u003C\u002Fp>\n\n\u003Cp>2. Your firm implemented change \u003Cstrong>(b)(4)\u003C\u002Fstrong> \"Modification of cTnI Sample Inlet Print for Mitigation of Interferences in the Field\" (effective: 06- Mar-2009) to increase the amount of caprine and murine IgG, and introduce murine IgM in the sample inlet&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> to reduce interferences. The change in reagent to reduce interference could have a direct impact on the device performance due to different interferences relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of reagent to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\u003C\u002Fp>\n\n\u003Cp>3. Your firm implemented \u003Cstrong>(b)(4)\u003C\u002Fstrong> \"Update supplier of \u003Cstrong>(b)(4)\u003C\u002Fstrong> for cTnI Base print\" (effective: 11-Feb- 2022) to allow the recipe for cTnI baseprint to use a secondary \u003Cstrong>(b)(4)\u003C\u002Fstrong> part number due to global supply shortage with the current supplier. The \u003Cstrong>(b)(4)\u003C\u002Fstrong> from the current supplier is \u003Cstrong>(b)(4)\u003C\u002Fstrong> and requires reconstitution prior to use, whereas the \u003Cstrong>(b)(4)\u003C\u002Fstrong> material from the secondary supplier is already in solution. A change to the secondary \u003Cstrong>(b)(4)\u003C\u002Fstrong> could have a direct impact on the device performance due to different interferences relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of \u003Cstrong>(b)(4)\u003C\u002Fstrong> to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\u003C\u002Fp>\n\n\u003Cp>4. Your firm implemented \u003Cstrong>(b)(4)\u003C\u002Fstrong> \"cTnI \u003Cstrong>(b)(4)\u003C\u002Fstrong> Cartridge and Tape Gasket Promote to Production\" (effective: 18-Jul- 2012) to modify the cTnI cartridge and gasket dipper\u002FDurapel diameters for use with \u003Cstrong>(b)(4)\u003C\u002Fstrong>\" chips to maintain product performance. This change could affect the signal reading of the cartridge and therefore impact the device’s ability to accurately measure troponin concentrations. This change of sensor chip specification significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\u003C\u002Fp>\n\n\u003Cp>Inaccurate troponin results, a time-critical analyte, due to these changes, may lead to false negative or false positive results which may lead to significant consequences to patients including death. The above-referenced changes, individually and collectively, significantly modified existing risks to the subject device and could significantly impact safety and effectiveness of the subject device. Your firm did not notify FDA of these significant changes before introducing the modified i-STAT cTnI cartridges into commercial distribution, and FDA has not received a new 510(k) for these modified devices to date. As a result, your current cTnI cartridge is unapproved because it is no longer considered to be substantially equivalent to the predicate devices described in your existing 510(k)s.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cstrong>Code of Federal Regulations\u003C\u002Fstrong> (CFR), Part 820. We received a response from you dated June 10, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). For example, during the inspection the investigator questioned your firm’s design personnel about cumulative changes. Your firm responded that you did not consider the cumulative effect of design changes over time and never compared the performance of the modified device change to the originally cleared device either through design controls or regulatory review. Further, your firm has made multiple design changes to the i-STAT cTnl (white) cartridge from 2003 to 2022 without assessing the cumulative effect of the changes on the device performance or comparing the modified device to the original or most recently cleared device design.\u003C\u002Fp>\n\n\u003Cp>We reviewed your response and concluded that it is not adequate. You provided a summarized “Review of the i-STAT IH\u002FTH sensor chip specification change and significant design changes for the i-STAT cTnI cartridge since 2003” dated June 10, 2022 in attachment 1.10 which included final product test disposition data from the last 10 cTnI lots in 2022 using the cTnI cartridges. A comparison of your current device’s specifications (2022) and original device’s specifications (2003) for the i-STAT Troponin I (cTnI) cartridge sensor chip was provided. However, the analytical sensitivity and the precision testing in whole blood and control fluids your firm used as part of its validation for design changes to the i-STAT cTnI cartridge has not demonstrated that this testing accurately and reliably predicts the impact of such changes on the clinical performance of your device. For example, the testing used to support your firm’s claims did not impact the performance of your device did not include a comparison of the modified device to the original device and key performance data such as clinical accuracy were not documented to support these design changes. You should provide a revised copy of your firm’s design control procedures which address the need for a cumulative review of design changes and their impact on the original device design, and evidence of training on the new or revised document. You should also conduct a systemic review of all device changes to determine if other device design changes were inadequately evaluated or documented.\u003C\u002Fp>\n\n\u003Cp>2. Failure to adequately maintain all records required by 21 CFR 820 at the manufacturing establishment or other location that is reasonably accessible to responsible officials of the manufacturer and to employees of FDA designated to perform inspections. Such records, including those not stored at the inspected establishment, shall be made readily available for review and copying by FDA employee(s), as required by 21 CFR 820.180. For example, during the inspection the investigator asked to review a copy of the original design to compare to any current changes. Your firm could not locate the original cartridge design files because the person in charge of storing the cartridge design history files had retired from the company and your firm had been trying to locate the person in retirement to try to find where the original design files where stored.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your firm’s response cannot be determined at this time. Your response states that your firm was able to locate the original drawing of the TH (IH1) chip containing the analyte and reference sensors for the i-STAT Troponin I (cTnI) test which were provided in attachment 1.11. You stated that the original record was in a location not referenced in \u003Cstrong>(b)(4)\u003C\u002Fstrong>, Quality Record Storage Procedure supporting documentation \u003Cstrong>(b)(4)\u003C\u002Fstrong> Record Location, although the location was being maintained as a record location. You also stated that you performed the correction including the update of the record location documents as required, reviewing and summarizing the current and original specifications for the i-STAT Troponin I (cTnI) cartridge sensor chip and provided in summary attachment 1.10 (Review of the i-STAT IH\u002FTH sensor chip specification change and significant design changes for the i-STAT cTnI cartridge since 2003). You further stated that your firm performed systemic correction action including updating the \u003Cstrong>(b)(4)\u003C\u002Fstrong> Record Location – Ottawa to include an additional cabinet location and completed all necessary personnel training. Your firm’s corrective actions will be verified at the next inspection.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #640946 when replying. If you have any questions about the contents of this letter, please contact: Xiaofen Huang at 240-402-1115.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Timothy T. Stenzel, M.D., Ph.D.\u003Cbr>\nDirector\u003Cbr>\nOHT 7: Office of In Vitro Diagnostics\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC:\u003Cbr>\nKerry Caldwell\u003Cbr>\nAbbott Point Of Care\u003Cbr>\nKerry.caldwell@abbott.com\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nEdward O’Neill\n\nRecipient Title\n\nDivisional Vice President, Manufacturing Operations\n\nAbbott Point of Care Canada Limited\n\n185 Corkstown Rd\n\nNepean ON K2H 8V4\n\nCanada\n\nTed.oneill@abbott.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nNovember 8, 2022\n\nDear Edward O’Neill:\n\nDuring an inspection of your firm located in Ottawa, Canada on May 16, 2022, through May 19, 2022, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures the i-STAT cTnI Test intended for the quantitative measurement of cardiac troponin I in whole blood or plasma. These measurements are intended to be used in the diagnosis and treatment of myocardial infarction and as an aid in the risk stratification of patients with acute coronary syndromes with respect to their relative risk of mortality. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that the i-STAT cTnI cartridges are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g), 21 U.S.C. § 360j(g), for this device. This device is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify FDA of its intent to introduce the devices into commercial distribution in a notice or other information respecting modifications to these devices was not provided to FDA, as required by section 510(k) of the Act, 21 U.S.C. § 360(k), and 21 CFR 807.81(a)(3).\n\nYour firm’s i-STAT cTnI Test was originally cleared for use with heparinized whole blood and plasma in K031739 and cleared for use with whole blood (not heparinized) in K051433. However, you have made multiple significant design changes to the i-STAT cTnI cartridge since 2003. For example:\n\n1. Your firm implemented change (b)(4) \"Alternate source of (b)(4)\" (effective: 05- May-2022) to update the material specification ((b)(4)) of the (b)(4) which is obtained from Sigma and used as an Interferent Eliminating Proteins (IEP) in the immune base prints. This supplier part number change was due to a process change that replaces monoclonal antibody production in live (b)(4) with production in cell culture. The alternate source of IgM that was used to reduce interference could have a direct impact on device performance due to different interference relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of (b)(4) to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and therefore, requires submission of a new premarket notification (510(k)).\n\n2. Your firm implemented change (b)(4) \"Modification of cTnI Sample Inlet Print for Mitigation of Interferences in the Field\" (effective: 06- Mar-2009) to increase the amount of caprine and murine IgG, and introduce murine IgM in the sample inlet (b)(4) to reduce interferences. The change in reagent to reduce interference could have a direct impact on the device performance due to different interferences relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of reagent to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\n\n3. Your firm implemented (b)(4) \"Update supplier of (b)(4) for cTnI Base print\" (effective: 11-Feb- 2022) to allow the recipe for cTnI baseprint to use a secondary (b)(4) part number due to global supply shortage with the current supplier. The (b)(4) from the current supplier is (b)(4) and requires reconstitution prior to use, whereas the (b)(4) material from the secondary supplier is already in solution. A change to the secondary (b)(4) could have a direct impact on the device performance due to different interferences relative to the original device and could change the ability of the device to accurately measure the troponin concentration. This change of (b)(4) to reduce interference significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\n\n4. Your firm implemented (b)(4) \"cTnI (b)(4) Cartridge and Tape Gasket Promote to Production\" (effective: 18-Jul- 2012) to modify the cTnI cartridge and gasket dipper\u002FDurapel diameters for use with (b)(4)\" chips to maintain product performance. This change could affect the signal reading of the cartridge and therefore impact the device’s ability to accurately measure troponin concentrations. This change of sensor chip specification significantly modified existing risks and could significantly affect the safety or effectiveness of the devices and requires submission of a new premarket notification (510(k)).\n\nInaccurate troponin results, a time-critical analyte, due to these changes, may lead to false negative or false positive results which may lead to significant consequences to patients including death. The above-referenced changes, individually and collectively, significantly modified existing risks to the subject device and could significantly impact safety and effectiveness of the subject device. Your firm did not notify FDA of these significant changes before introducing the modified i-STAT cTnI cartridges into commercial distribution, and FDA has not received a new 510(k) for these modified devices to date. As a result, your current cTnI cartridge is unapproved because it is no longer considered to be substantially equivalent to the predicate devices described in your existing 510(k)s.\n\nOur inspection also revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received a response from you dated June 10, 2022, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation, as required by 21 CFR 820.30(i). For example, during the inspection the investigator questioned your firm’s design personnel about cumulative changes. Your firm responded that you did not consider the cumulative effect of design changes over time and never compared the performance of the modified device change to the originally cleared device either through design controls or regulatory review. Further, your firm has made multiple design changes to the i-STAT cTnl (white) cartridge from 2003 to 2022 without assessing the cumulative effect of the changes on the device performance or comparing the modified device to the original or most recently cleared device design.\n\nWe reviewed your response and concluded that it is not adequate. You provided a summarized “Review of the i-STAT IH\u002FTH sensor chip specification change and significant design changes for the i-STAT cTnI cartridge since 2003” dated June 10, 2022 in attachment 1.10 which included final product test disposition data from the last 10 cTnI lots in 2022 using the cTnI cartridges. A comparison of your current device’s specifications (2022) and original device’s specifications (2003) for the i-STAT Troponin I (cTnI) cartridge sensor chip was provided. However, the analytical sensitivity and the precision testing in whole blood and control fluids your firm used as part of its validation for design changes to the i-STAT cTnI cartridge has not demonstrated that this testing accurately and reliably predicts the impact of such changes on the clinical performance of your device. For example, the testing used to support your firm’s claims did not impact the performance of your device did not include a comparison of the modified device to the original device and key performance data such as clinical accuracy were not documented to support these design changes. You should provide a revised copy of your firm’s design control procedures which address the need for a cumulative review of design changes and their impact on the original device design, and evidence of training on the new or revised document. You should also conduct a systemic review of all device changes to determine if other device design changes were inadequately evaluated or documented.\n\n2. Failure to adequately maintain all records required by 21 CFR 820 at the manufacturing establishment or other location that is reasonably accessible to responsible officials of the manufacturer and to employees of FDA designated to perform inspections. Such records, including those not stored at the inspected establishment, shall be made readily available for review and copying by FDA employee(s), as required by 21 CFR 820.180. For example, during the inspection the investigator asked to review a copy of the original design to compare to any current changes. Your firm could not locate the original cartridge design files because the person in charge of storing the cartridge design history files had retired from the company and your firm had been trying to locate the person in retirement to try to find where the original design files where stored.\n\nThe adequacy of your firm’s response cannot be determined at this time. Your response states that your firm was able to locate the original drawing of the TH (IH1) chip containing the analyte and reference sensors for the i-STAT Troponin I (cTnI) test which were provided in attachment 1.11. You stated that the original record was in a location not referenced in (b)(4), Quality Record Storage Procedure supporting documentation (b)(4) Record Location, although the location was being maintained as a record location. You also stated that you performed the correction including the update of the record location documents as required, reviewing and summarizing the current and original specifications for the i-STAT Troponin I (cTnI) cartridge sensor chip and provided in summary attachment 1.10 (Review of the i-STAT IH\u002FTH sensor chip specification change and significant design changes for the i-STAT cTnI cartridge since 2003). You further stated that your firm performed systemic correction action including updating the (b)(4) Record Location – Ottawa to include an additional cabinet location and completed all necessary personnel training. Your firm’s corrective actions will be verified at the next inspection.\n\nFor a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #640946 when replying. If you have any questions about the contents of this letter, please contact: Xiaofen Huang at 240-402-1115.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nTimothy T. Stenzel, M.D., Ph.D.\n\nDirector\n\nOHT 7: Office of In Vitro Diagnostics\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC:\n\nKerry Caldwell\n\nAbbott Point Of Care\n\nKerry.caldwell@abbott.com","Abbott Point of Care Canada Limited","abbott-point-care-canada-limited-640946-11082022","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fabbott-point-care-canada-limited-640946-11082022","2026-10-26T08:07:48.732311+00:00","2023-04-19","640946","Edward O’Neill","2026-08-20T01:09:04.748+00:00","2022-11-08",3,{"510k":78,"classification":79,"enforcement":80,"event":81,"event_backfill":82,"pma":83,"warning_letter":84},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-17T04:00:34.414+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]